nmCRPC VL

The PROSPER Trial: Enzalutamide Demonstrates Significant Improvement in Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer - Cora Sternberg

Details
Cora Sternberg, MD, FACP, shares the final analysis of the PROSPER trial assessing enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC). In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation ther...

Overall Survival Results of Phase III ARAMIS Study of Darolutamide Added to ADT for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - Karim Fizazi

Details
Darolutamide is a structurally unique androgen-receptor antagonist that is approved for the treatment of prostate cancer. ARAMIS is a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer, and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive daroluta...

ARAMIS Trial: Darolutamide Demonstrates Improved Overall Survival in Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) - Fred Saad

Details
Fred Saad provides his perspective on the newest ARAMIS trial results, presented at ASCO 2020. Results from the phase III androgen receptor inhibiting agent for metastatic-free survival (ARAMIS) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a significant improvement in delaying the time to death in patients receiving darolutami...

Treatment Advances in Non-Metastatic Castration-Resistant Prostate Cancer - Evan Yu

Details
Evan Yu joins Alicia Morgans to discuss treatment advances in the non-metastatic castration-resistant prostate cancer space, focusing on the data and clinical implications of the ARAMIS trial. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies, as well as...

Prolonging Overall Survival in Men with Non-metastatic Castration Resistant Prostate Cancer ARAMIS Trial - Neal Shore

Details
In this conversation with Alicia Morgans, Neal Shore talks about the three new approved agents in the non-metastatic, castration-resistant prostate cancer (CRPC) setting; apalutamide, enzalutamide, and darolutamide and specifically highlight the urge for findings of prolonged survival, which have now been reported from both enzalutamide in the PROSPER trial and darolutamide in the ARAMIS trial. To...

Benefits of Early AR Targeting in Metastatic Hormone Sensitive Disease and nmCRPC - Karim Fizazi

Details
Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...

Considerations for the Treatment of Non Metastatic Castration-Resistant Prostate Cancer - An Interview with Maha Hussain and Tia Higano

Details
Tia Higano and Maha Hussain share highlights of their 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentations with Alicia Morgans. Drs. Higano and Hussain presented opposing presentations on the pros and cons of treatment in the nonmetastatic castration-resistant prostate cancer setting. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in t...

Systemic Therapies for Node-Positive Non-Metastatic Castration Resistant Prostate Cancer - Nicholas James

Details
Nicholas James joins Alicia Morgans at the Advanced Prostate Cancer Consensus Conference (APCCC) to discuss systemic therapies for node-positive patients. Professor James discusses the three main questions to his presentation: What's the role of radiotherapy? What systemic therapies do you give with radiotherapy? Do you give ADT plus something else? Biographies: Professor Nicholas James BSc, MB, B...

Long-term Follow-up of Non-metastatic (M0) Patients in the STAMPEDE Randomized Trial - Interview with Nicholas James

Details
Nick James and Alicia Morgans talk about the newly presented STAMPEDE data just released and presented at the 2019 ESMO meeting including, long-term follow-up of the docetaxel patients as well as the much anticipated metastatic data. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncolo...

Optimal Treatment of Newly Diagnosed Metastatic Prostate Cancer Presentation - Noel Clarke

Details
Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...
email news signup